A fail­ure at Eli Lil­ly, the come­back drug teplizum­ab shows off more up­beat di­a­betes da­ta in the run-up to an FDA fil­ing

Proven­tion Bio has some more pos­i­tive da­ta to add to its loom­ing BLA for a new treat­ment de­signed to de­lay the on­set of di­a­betes among pa­tients.

Their new tri­al da­ta for teplizum­ab boost­ed the av­er­age amount of time it takes for a pa­tient to be di­ag­nosed with type 1 di­a­betes to 5 years, adding a year to their ear­li­er num­ber com­pared to a steady 2 years for the place­bo arm.

Re­searchers added that they are track­ing clear ev­i­dence that the drug can sta­bi­lize and then re­verse de­te­ri­o­rat­ing C-pep­tide lev­els, “sug­gest­ing a de­lay in the de­struc­tion of be­ta cells and restora­tion of in­sulin pro­duc­tion by dys­func­tion­al be­ta cells. Im­por­tant­ly, even in those who ad­vanced to clin­i­cal-stage T1D, treat­ment with teplizum­ab re­sult­ed in a slow­er de­cline in C-pep­tide lev­els com­pared to place­bo.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.